DE1620262C3 - Spiro [4.5] decanderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen - Google Patents

Spiro [4.5] decanderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen

Info

Publication number
DE1620262C3
DE1620262C3 DE1620262A DES0096461A DE1620262C3 DE 1620262 C3 DE1620262 C3 DE 1620262C3 DE 1620262 A DE1620262 A DE 1620262A DE S0096461 A DES0096461 A DE S0096461A DE 1620262 C3 DE1620262 C3 DE 1620262C3
Authority
DE
Germany
Prior art keywords
spiro
decane
compounds
oxo
oxa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE1620262A
Other languages
German (de)
English (en)
Other versions
DE1620262B2 (de
DE1620262A1 (de
Inventor
Roger La Haye Les Roses Canevari
Jean- Claude Le Suresnes Douarec
Gilbert Sceaux Regnier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SCIENCE UNION ET CIE (SOCIETE FRANCAISE DE RECHERCHE MEDICALE) SURESNES HAUTS-DE-SEINE (FRANKREICH)
Original Assignee
SCIENCE UNION ET CIE (SOCIETE FRANCAISE DE RECHERCHE MEDICALE) SURESNES HAUTS-DE-SEINE (FRANKREICH)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SCIENCE UNION ET CIE (SOCIETE FRANCAISE DE RECHERCHE MEDICALE) SURESNES HAUTS-DE-SEINE (FRANKREICH) filed Critical SCIENCE UNION ET CIE (SOCIETE FRANCAISE DE RECHERCHE MEDICALE) SURESNES HAUTS-DE-SEINE (FRANKREICH)
Publication of DE1620262A1 publication Critical patent/DE1620262A1/de
Publication of DE1620262B2 publication Critical patent/DE1620262B2/de
Application granted granted Critical
Publication of DE1620262C3 publication Critical patent/DE1620262C3/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
DE1620262A 1964-04-22 1965-04-09 Spiro [4.5] decanderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen Expired DE1620262C3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB16696/64A GB1100281A (en) 1964-04-22 1964-04-22 New spiro-decane derivatives and process for the preparation thereof

Publications (3)

Publication Number Publication Date
DE1620262A1 DE1620262A1 (de) 1972-03-23
DE1620262B2 DE1620262B2 (de) 1979-10-11
DE1620262C3 true DE1620262C3 (de) 1980-07-03

Family

ID=10081982

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1620262A Expired DE1620262C3 (de) 1964-04-22 1965-04-09 Spiro [4.5] decanderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen

Country Status (9)

Country Link
US (1) US3399192A (OSRAM)
BE (1) BE662817A (OSRAM)
CH (1) CH454160A (OSRAM)
DE (1) DE1620262C3 (OSRAM)
ES (2) ES312091A1 (OSRAM)
FR (2) FR1441575A (OSRAM)
GB (1) GB1100281A (OSRAM)
NL (2) NL6504602A (OSRAM)
SE (1) SE307793B (OSRAM)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL129025C (OSRAM) * 1965-04-29
US3542729A (en) * 1968-03-19 1970-11-24 Sankyo Co Stabilization of synthetic polymers
BE790675A (fr) * 1971-10-29 1973-04-27 Science Union & Cie Nouveaux derives de l'oxa-1 diaza-3,8 spiro (4,5) decane
US4244961A (en) * 1978-10-26 1981-01-13 Syntex (U.S.A.) Inc. 1-Oxa-3,8-diazaspiro[4.5]decan-2-ones antihypertensive agents
US4255432A (en) * 1979-09-06 1981-03-10 Syntex (U.S.A.) Inc. 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
ES8401072A1 (es) * 1982-11-23 1983-12-16 Faes Procedimiento de preparacion de un nuevo espirodecano.
YU150489A (sh) * 1989-08-10 1992-12-21 W.L. Gore & Co. Gmbh. Uređaj za ispitivanje odevnih predmeta na nepromočivost
HU204054B (en) * 1989-08-10 1991-11-28 Richter Gedeon Vegyeszet Process for producing new 1-oxa-2-oxo-8-azaspiro(4,5)decane derivatives and pharmaceutical compositions comprising same
FR2666583B1 (fr) * 1990-09-06 1994-09-09 Adir Nouveaux derives du spiro [4.5] decane, leur procede de preparation et leurs compositions pharmaceutiques les renfermant.
FR2734265B1 (fr) * 1995-05-17 1997-06-13 Adir Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
WO2002058685A2 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
JP2004521894A (ja) * 2001-01-26 2004-07-22 シェーリング　コーポレイション 胆汁酸金属イオン封鎖剤およびステロール吸収阻害剤の併用および血管適応症の治療
ES2274013T3 (es) * 2001-01-26 2007-05-16 Schering Corporation Combinaciones de activador(es) del receptor activado por el proliferador de los peroxisomas (ppar) e inhibidor(es)m de la absorcion de estelores y tratamientos para trastornos vasculares.
CA2434436A1 (en) * 2001-01-26 2002-08-01 Teddy Kosoglou Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
CA2434430A1 (en) * 2001-01-26 2002-08-01 Harry R. Davis The use of substituted azetidinone compounds for the treatment of sitosterolemia
BR0206639A (pt) * 2001-01-26 2004-02-25 Schering Corp Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
EP1392287B8 (en) * 2001-05-25 2007-01-10 Schering Corporation Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
DE10130020A1 (de) * 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
DE10146275A1 (de) 2001-09-18 2003-04-24 Gruenenthal Gmbh Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
AU2002336609B2 (en) * 2001-09-21 2006-08-24 Merck Sharp & Dohme Corp. Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
DE60229406D1 (de) * 2001-09-21 2008-11-27 Schering Corp Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
ATE502635T1 (de) 2002-08-19 2011-04-15 Pfizer Kombinationstherapie gegen hyperproliferative erkrankungen
WO2004043457A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
WO2004081004A1 (en) * 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
WO2005046797A2 (en) * 2003-11-05 2005-05-26 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
CA2554671A1 (en) 2004-02-10 2005-08-18 F.Hoffmann-La Roche Ag Chemokine ccr5 receptor modulators
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
BRPI0809646A2 (pt) * 2007-03-29 2014-09-23 Hoffmann La Roche Compostod antivirais heterocíclicos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN102766147B (zh) * 2012-08-03 2015-07-15 无锡药兴医药科技有限公司 一种芬司匹利及其氢卤酸盐的制备方法
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
GB201416346D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3193559A (en) * 1965-07-06 New derivatives of z-oxazolidinones
US2437388A (en) * 1948-03-09 Z-oxazolidone compounds and proc
US2500714A (en) * 1944-10-30 1950-03-14 Abbott Lab 4-phenyl-1-alkyl isonipecotic acid lactones
US3054794A (en) * 1958-01-17 1962-09-18 Us Vitamin Pharm Corp Process for preparing 3-(aminoalkyl)-oxazolidine-2, 4-diones
GB974134A (en) * 1963-03-28 1964-11-04 Science Union Et Compagnie Soc Oxazolidinone derivatives

Also Published As

Publication number Publication date
NL127065C (OSRAM)
FR4463M (OSRAM) 1966-09-26
US3399192A (en) 1968-08-27
DE1620262B2 (de) 1979-10-11
GB1100281A (en) 1968-01-24
FR1441575A (fr) 1966-06-10
BE662817A (OSRAM) 1965-10-21
ES312091A1 (es) 1965-10-01
CH454160A (fr) 1968-04-15
DE1620262A1 (de) 1972-03-23
SE307793B (OSRAM) 1969-01-20
ES361975A2 (es) 1971-01-16
NL6504602A (OSRAM) 1965-10-25

Similar Documents

Publication Publication Date Title
DE1620262C3 (de) Spiro [4.5] decanderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
DD202152A5 (de) Verfahren zur herstellung von phenylpiperazinderivaten
EP0000928A1 (de) Neue Nitroimidazole und diese enthaltende pharmazeutische Präparate sowie deren Herstellung
EP0000220A1 (de) Dihydrouracile, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
DE2162011C3 (de) 2-Phenyl-3-(4-methyl-piperazinocarbonyloxy)-1-isoindolinon-derivate, ihre Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DE2044172C3 (de) Pyrrolderivate, ein Verfahren zu ihrer Herstellung und Arzneimittel
DE1914571B2 (de) L-3hydroxy-6-oxomorphinan-verbindungen
EP0000395B1 (de) 2-Piperazinotetraline, ihre Herstellung und Verwendung als Arzneimittel
EP0110869A1 (de) Thienylessigsäureamidderivate und pharmazeutisch verträgliche Säureadditionssalze hiervon sowie Verfahren zu deren Herstellung
DE1518452B2 (de) 4-substituierte 2-benzhydryl-2butanol-derivate und verfahren zu ihrer herstellung
DE2412520C2 (de) Tricyclische Verbindungen, Verfahren zu deren Herstellung und diese enthaltende Präparate
DE2457309A1 (de) 2-phenylhydrazinothiazolin- beziehungsweise 2-phenylhydrazinothiazininderivate sowie ihre verwendung und verfahren zur herstellung derselben
DE1944759B2 (de) 3-Indolylacetamide, ihre Salze und Verfahren zu ihrer Herstellung
DE2636866A1 (de) Neue phenothiazinderivate und deren herstellung
DE2528194C2 (de) Benzhydryloxyäthylamin-Derivate, deren Salze, Verfahren zur Herstellung derselben und solche enthaltende Arzneimittel
DE2656678C2 (de) 4-Amino-trans-decahydrochinolin-Derivate und Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DD142875A5 (de) Verfahren zur herstellung von 2-aminoaethanolderivaten
CH634545A5 (en) 1-Phenyl-1-methoxy-2-aminoethane derivatives, and a process for their preparation
DE1092476B (de) Verfahren zur Herstellung von Phenthiazinderivaten
CH636875A5 (de) 4,5,6,7-tetrahydroimidazo(4,5-c)pyridinderivate und verfahren zu ihrer herstellung.
DE2430510A1 (de) Amide der dihydroapovincaminsaeure
DE3873720T2 (de) Nicotinoylpiperazin-derivate, verfahren zu ihrer herstellung und ihre verwendung in der therapie.
DE2215545C3 (de) Pyridin-2-carbonsäurepiperazide
DE1620171A1 (de) Verfahren zur Herstellung von heterocyclischen Verbindungen
DE1470084A1 (de) Verfahren zur Herstellung von substituierten Piperidin-derivaten

Legal Events

Date Code Title Description
C3 Grant after two publication steps (3rd publication)